ESMO-MCBS and health technology assessment (HTA): Does value for physicians correspond to value for payers?

被引：0
|
作者：
Ambavane, A. [1 ]
Benedict, A. [2 ]
Rivolo, S. [3 ]
Rakonczai, P. [2 ]
Kapetanakis, V. [4 ]
机构：
[1] Evidera Inc, Evidence Synth Modeling & Commun, Dubai, U Arab Emirates
[2] Evidera Inc, Evidence Synth Modeling & Commun, Budapest, Hungary
[3] Evidera Inc, Evidence Synth Modeling & Commun, Angera, Italy
[4] Evidera Inc, Evidence Synth Modeling & Commun, London, England
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1626O
引用
收藏
页码：671 / 671
页数：1
相关论文
共 50 条
  • [31] Health Technology Assessment Challenges in Oncology: 20 Years of Value in Health
    Kim, Hansoo
    Goodall, Stephen
    Liew, Danny
    VALUE IN HEALTH, 2019, 22 (05) : 593 - 600
  • [32] DOES THE TREND TOWARDS VALUE FRAMEWORKS REQUIRE NEW APPROACHES TO EVIDENCE DEVELOPMENT AND HEALTH TECHNOLOGY ASSESSMENT?
    Teale, C. W.
    Entwistle, J.
    Freeman, S.
    VALUE IN HEALTH, 2016, 19 (07) : A763 - A763
  • [33] Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts
    Postma, Maarten
    Biundo, Eliana
    Chicoye, Annie
    Devlin, Nancy
    Mark Doherty, T.
    Garcia-Ruiz, Antonio J.
    Jaros, Patrycja
    Sheikh, Shazia
    Toumi, Mondher
    Wasem, Juergen
    Beck, Ekkehard
    Salisbury, David
    Nolan, Terry
    VACCINE, 2022, 40 (29) : 3999 - 4007
  • [34] Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts
    Postma, Maarten
    Biundo, Eliana
    Chicoye, Annie
    Devlin, Nancy
    Doherty, T. Mark
    Garcia-Ruiz, Antonio J.
    Jaros, Patrycja
    Sheikh, Shazia
    Toumi, Mondher
    Wasem, Jurgen
    Beck, Ekkehard
    Salisbury, David
    Nolan, Terry
    VACCINE, 2022, 40 (30) : 3999 - 4007
  • [35] Early health technology assessment: the value of valuing AI applications
    Vermeulen, Robin Jeanna
    Govers, Tim Martin
    van Leeuwen, Kicky Gerhilde
    EUROPEAN RADIOLOGY, 2024, 34 (09) : 5854 - 5855
  • [36] Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment
    Soares, Marta O.
    Walker, Simon
    Palmer, Stephen J.
    Sculpher, Mark J.
    MEDICAL DECISION MAKING, 2018, 38 (04) : 495 - 508
  • [37] The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment
    McElwee, Frederick
    Newall, Anthony
    PHARMACOECONOMICS, 2024, 42 (SUPPL 2) : 187 - 197
  • [38] Value drivers for pharmaceutical products in health technology assessment (HTA) in Saudi Arabia: Results from a capacity Building, Multi-Stakeholder workshop
    Al-Omar, Hussain A.
    Aljuffali, Ibrahim A.
    Sola-Morales, Oriol
    SAUDI PHARMACEUTICAL JOURNAL, 2021, 29 (09) : 946 - 954
  • [39] DOES USING CLINICAL TRIALS IN HEALTH TECHNOLOGY ASSESSMENT (HTA) ECONOMIC MODELLING IMPACT REIMBURSEMENT DECISIONS?
    Inumerable, R. V. F.
    Rubinstein, J.
    VALUE IN HEALTH, 2020, 23 : S139 - S139
  • [40] UNDERSTANDING THE VALUE OF REAL-WORLD EVIDENCE (RWE) IN HEALTH ECONOMICS: ARE TRADITIONAL SYSTEMATIC LITERATURE REVIEWS (SLRS) OMITTING KEY EVIDENCE FOR HEALTH TECHNOLOGY ASSESSMENT (HTA)?
    Richard, M. E.
    Harricharan, S.
    Forsythe, A.
    VALUE IN HEALTH, 2021, 24 : S53 - S53
12345